---

$0.02

-0.0005 ( -3.04% ) 3.5K

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-10-09	Buy	5431.00	Fraser Craig
2024-07-24	Sale	-19.00	Fraser Craig
2024-07-24	Sale	-13.00	Simonson Steven
2023-09-28	Buy	2500.00	Fraser Craig
2023-09-27	Buy	2500.00	Fraser Craig
2023-08-29	Sale	-2033.00	Geffken Daniel E.
2023-08-25	Sale	-2033.00	SCOTT ROBERT A
2023-08-25	Sale	-2300.00	Strobeck Mark
2023-08-25	Sale	-15867.00	Simonson Steven
2023-08-25	Sale	-14667.00	Curtis Eric